Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (GB:0QAH)
LSE:0QAH
Merck & Company (0QAH) Share Price & Analysis
4 Followers
0QAH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$97.81 - $133.08
Previous Close$127
Volume24.67K
Average Volume (3M)198.18K
Market Cap
$321.34B
Enterprise Value$349.36B
Total Cash (Recent Filing)$7.09B
Total Debt (Recent Filing)$35.05B
Price to Earnings (P/E)886.3
Beta0.36
Next Earnings
Apr 25, 2024EPS Estimate
$1.9Last Dividend Ex-Date
Mar 14, 2024Dividend Yield2.36%
Share Statistics
EPS (TTM)0.13
Shares Outstanding2,532,643,872
10 Day Avg. Volume47,622
30 Day Avg. Volume198,177
Standard Deviation0.05
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-197.51
Price to Sales (P/S)3.24
Price to Cash Flow (P/CF)326.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.81
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda68.68
Forecast
1Y Price Target
$135.44Price Target Upside6.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Sales ForecastWinrevair, also known as sotatercept, has been approved with a clean label for the treatment of pulmonary arterial hypertension, signaling a significant de-risking event and setting the stage for robust sales growth.
Financial Performance And GrowthAnalysts have raised their peak sales projection for Winrevair to around $11 billion, indicating a much more optimistic outlook than previous consensus, which could reflect positively on the stock value.
Product Demand And Market PenetrationThe demand for vaccines, particularly Gardasil, remains strong in China, which could contribute to a substantial upside in sales for the company.
Bears Say
Drug EfficacyWhile the triplet therapy led to more Grade 3-5 AEs, study drug discontinuations, and deaths - including two deaths due to pneumonitis - compared to the other two arms.
Financial PerformanceVAXNEUVANCE 4Q23 sales were $176 mln - below Mizuho and Bloomberg estimates.
Regulatory SetbacksThere was a $779M asset impairment for gefapixant, following FDA's CRL.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
21.72% Mutual Funds
20.82% Other Institutional Investors
57.29% Public Companies and
Individual Investors
0QAH FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest share price was $97.81 and its highest was $133.08 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 25, 2024 which is yesterday.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 01, 2024. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.138.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.36%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $1.9.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,532,643,800 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went up 2.556%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 1B.
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.44 (6.90% Upside)
$135.44 (6.90% Upside)
Blogger Sentiment
Bullish
GB:0QAH Sentiment 93%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $49.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.53%
12-Months-Change
Fundamentals
Return on Equity
0.87%
Trailing 12-Months
Asset Growth
-2.28%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
0QAH Company Deck
---
0QAH Earnings Call
Q4 2024
0:00 / 0:00
---
0QAH Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
0QAH Stock 12 Months Forecast
Average Price Target
$135.44
▲(6.90% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Johnson & Johnson
―
Bristol-Myers Squibb
―
GlaxoSmithKline
―
Best Analysts Covering 0QAH
1 Year
1 Year Success Rate
13/13 ratings generated profit
1 Year Average Return
+22.23%
assigned a buy rating 29 days ago
Copying Robyn Karnauskas's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.23% per trade.
---